BACKGROUND AND PURPOSE: Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers. In this phase I trial, we aimed to determine the toxicity of [(18)F]HX4, a member of the 2-nitroimidazole family, at different dose levels. The secondary aim was to analyse image quality related to the HX4 dose and the timing of imaging. METHODS: Patients with a histologically proven solid cancer without curative treatment options were eligible for this study. A study design with two dose steps was used in which a single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [(18)F]HX4 was injected. Toxicity was scored on day 0 and on days 3 and 7 after injection, according to the CTCAE 3.0 scoring system. PET/CT images of the largest tumour site were acquired 30, 60 and 120 min after injection. RESULTS: Six patients with stage IV carcinoma were included, four with non-small-cell lung carcinoma, one with thymus carcinoma, and one with colon carcinoma. No toxicity was observed in any of the patients at either dose level. The median tumour to muscle ratio 120 min after injection was 1.40 (range 0.63-1.98). CONCLUSION: The findings of this study showed that [(18)F]HX4 PET imaging for the detection of hypoxia is not associated with any toxicity. Imaging was successful; however, future trials are needed to determine the optimal image parameters.
BACKGROUND AND PURPOSE: Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers. In this phase I trial, we aimed to determine the toxicity of [(18)F]HX4, a member of the 2-nitroimidazole family, at different dose levels. The secondary aim was to analyse image quality related to the HX4 dose and the timing of imaging. METHODS:Patients with a histologically proven solid cancer without curative treatment options were eligible for this study. A study design with two dose steps was used in which a single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [(18)F]HX4 was injected. Toxicity was scored on day 0 and on days 3 and 7 after injection, according to the CTCAE 3.0 scoring system. PET/CT images of the largest tumour site were acquired 30, 60 and 120 min after injection. RESULTS: Six patients with stage IV carcinoma were included, four with non-small-cell lung carcinoma, one with thymus carcinoma, and one with colon carcinoma. No toxicity was observed in any of the patients at either dose level. The median tumour to muscle ratio 120 min after injection was 1.40 (range 0.63-1.98). CONCLUSION: The findings of this study showed that [(18)F]HX4 PET imaging for the detection of hypoxia is not associated with any toxicity. Imaging was successful; however, future trials are needed to determine the optimal image parameters.
Authors: Michel Ollers; Geert Bosmans; Angela van Baardwijk; Andre Dekker; Philippe Lambin; Jaap Teule; Willie Thimister; Ali Rhamy; Dirk De Ruysscher Journal: Radiother Oncol Date: 2008-01-22 Impact factor: 6.280
Authors: B G Wouters; S A Weppler; M Koritzinsky; W Landuyt; S Nuyts; J Theys; R K Chiu; P Lambin Journal: Eur J Cancer Date: 2002-01 Impact factor: 9.162
Authors: Morand Piert; Hans-Jürgen Machulla; Maria Picchio; Gerald Reischl; Sybille Ziegler; Piyush Kumar; Hans-Jürgen Wester; Roswitha Beck; Alexander J B McEwan; Leonard I Wiebe; Markus Schwaiger Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057
Authors: Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher Journal: Eur J Cancer Date: 2007-05-23 Impact factor: 9.162
Authors: Uulke A van der Heide; Antonetta C Houweling; Greetje Groenendaal; Regina G H Beets-Tan; Philippe Lambin Journal: Magn Reson Imaging Date: 2012-07-06 Impact factor: 2.546
Authors: Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb Journal: Antioxid Redox Signal Date: 2014-05-09 Impact factor: 8.401